ALNYLAM PHARMACEUTICALS, INC. (ALNY)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 773,689 | 594,189 | 500,919 | 659,825 |
| Selling, general and administrative | 323,314 | 239,949 | 220,993 | 248,397 |
| Research and development | 323,621 | 265,122 | 270,926 | 294,142 |
| Cost of goods sold | 142,029 | 70,183 | 81,980 | 67,271 |
| Cost of collaborations and royalties | 924 | 858 | 3,925 | 1,401 |
| Total operating costs and expenses | 789,888 | 576,112 | 577,824 | 611,211 |
| (loss) income from operations | -16,199 | 18,077 | -76,905 | 48,614 |
| Other expense, net | -6,399 | -49,700 | -29,528 | -55,705 |
| Interest income | 27,486 | 28,673 | 32,146 | 29,182 |
| Interest expense | 40,246 | 38,646 | 34,376 | 33,258 |
| Total other expense, net | -19,159 | -59,673 | -31,758 | -59,781 |
| Loss before income taxes | -35,358 | -41,596 | -108,663 | -11,167 |
| Provision for income taxes | 30,919 | 15,883 | 2,907 | 5,722 |
| Net loss | -66,277 | -57,479 | -111,570 | -16,889 |
| Unrealized (loss) gain on marketable securities | -343 | 1,030 | 9,078 | -727 |
| Foreign currency translation gain (loss) | 7,855 | - | - | - |
| Defined benefit pension plans, net of tax | -53 | - | - | - |
| Net other comprehensive income (loss) | 7,565 | - | - | - |
| Defined benefit pension plans, net of tax | - | -55 | -30 | -30 |
| Foreign currency translation loss | - | -4,084 | 703 | -6,952 |
| Total other comprehensive loss | - | -2,999 | 9,811 | -7,649 |
| Comprehensive loss | -58,712 | -60,478 | -101,759 | -24,538 |
| Net loss per common share - basic (in dollars per share) | -0.51 | -0.44 | -0.87 | -0.13 |
| Net loss per common share - diluted (in dollars per share) | -0.51 | -0.44 | -0.87 | -0.13 |
| Weighted-average common shares used to compute - basic (in shares) | 130,628,000 | 129,676,000 | 128,590,000 | 126,733,000 |
| Weighted-average common shares used to compute - diluted (in shares) | 130,628,000 | 129,676,000 | 128,590,000 | 126,733,000 |